Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 17:14:1127134.
doi: 10.3389/fendo.2023.1127134. eCollection 2023.

Correlation of multiple lipid and lipoprotein ratios with nonalcoholic fatty liver disease in patients with newly diagnosed type 2 diabetic mellitus: A retrospective study

Ran Li  1 , Dehong Kong  1 , Zhengqin Ye  1 , Guannan Zong  1 , Kerong Hu  1 , Wei Xu  1 , Ping Fang  1 , Liya Zhang  1 , Yun Zhou  1 , Keqin Zhang  1 , Ying Xue  1
Affiliations

Correlation of multiple lipid and lipoprotein ratios with nonalcoholic fatty liver disease in patients with newly diagnosed type 2 diabetic mellitus: A retrospective study

Ran Li et al. Front Endocrinol (Lausanne). .

Abstract

Background and objective: The diagnostic value of lipid and lipoprotein ratios for NAFLD in newly diagnosed T2DM remains unclear. This study aimed to investigate the relationships between lipid and lipoprotein ratios and the risk of NAFLD in subjects with newly diagnosed T2DM.

Methods: A total of 371 newly diagnosed T2DM patients with NAFLD and 360 newly diagnosed T2DM without NAFLD were enrolled in the study. Demographics variables, clinical history and serum biochemical indicators of the subjects were collected. Six lipid and lipoprotein ratios, including triglycerides to high-density lipoprotein-cholesterol (TG/HDL-C) ratio, cholesterol to HDL-C (TC/HDL-C) ratio, free fatty acid to HDL-C (FFA/HDL-C) ratio, uric acid to HDL-C (UA/HDL-C) ratio, low-density lipoprotein-cholesterol to HDL-C (LDL-C/HDL-C) ratio, apolipoprotein B to apolipoprotein A1 (APOB/A1) ratio, were calculated. We compared the differences in lipid and lipoprotein ratios between NAFLD group and non-NAFLD group, and further analyzed the correlation and diagnostic value of these ratios with the risk of NAFLD in the newly diagnosed T2DM patients.

Results: The proportion of NAFLD in patients with newly diagnosed T2DM increased progressively over the range Q1 to Q4 of six lipid ratios, including the TG/HDL-C ratio, TC/HDL-C ratio, FFA/HDL-C ratio, UA/HDL-C ratio, LDL-C/HDL-C ratio, and APOB/A1 ratio. After adjusting for multiple confounders, TG/HDL-C, TC/HDL-C, UA/HDL-C, LDL-C/HDL-C and APOB/A1 were all strongly correlated with the risk of NAFLD in patients with newly diagnosed T2DM. In patients with newly-onset T2DM, the TG/HDL-C ratio was the most powerful indicator for the diagnosis of NAFLD among all six indicators, with an area under the curve (AUC) of 0.732 (95% CI 0.696-0.769). In addition, TG/HDL-C ratio>1.405, with a sensitivity of 73.8% and specificity of 60.1%, had a good diagnostic ability for NAFLD in patients with newly diagnosed T2DM.

Conclusions: The TG/HDL-C ratio may be an effective marker to help identify the risk of NAFLD in patients with newly diagnosed T2DM.

Keywords: NAFLD; TG/HDL-C ratio; lipid ratios; lipoprotein ratios; newly diagnosed T2DM.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Proportion of NAFLD in patients with newly diagnosed T2DM across the quartiles of multiple lipid ratios (Q1-Q4). *P<0.001 vs. Q1. NAFLD, non-alcoholic fatty liver disease; T2DM, type 2 diabetes mellitus; TG/HDL-C, triglycerides to high-density lipoprotein-cholesterol ratio; TC/HDL-C, cholesterol to HDL-C ratio; FFA/HDL-C, free fatty acid to HDL-C ratio; UA/HDL-C, uric acid to HDL-C ratio; LDL-C/HDL-C, low-density lipoprotein-cholesterol to HDL-C ratio; APOB/A1, apolipoprotein B to apolipoprotein A1 ratio.
Figure 2
Figure 2
ROC curves of the six lipid ratios in patients with newly diagnosed T2DM combined with NAFLD. TG/HDL-C, triglycerides to high-density lipoprotein-cholesterol ratio; TC/HDL-C, cholesterol to HDL-C ratio; FFA/HDL-C, free fatty acid to HDL-C ratio; UA/HDL-C, uric acid to HDL-C ratio; LDL-C/HDL-C, low-density lipoprotein-cholesterol to HDL-C ratio; APOB/A1, apolipoprotein B to apolipoprotein A1 ratio; ROC curves, receiver operator characteristic curves; NAFLD, non-alcoholic fatty liver disease; T2DM, type 2 diabetes mellitus.
Figure 3
Figure 3
ROC curves for Model 3 of the six lipid ratios in patients with newly diagnosed T2DM combined with NAFLD. Model 3 is adjusted for age, sex, current smoking, BMI, ALT, AST, GGT, ALP, Scr, FBG, HbA1c and FINS. NAFLD, non-alcoholic fatty liver disease; T2DM, type 2 diabetes mellitus; ROC curves, receiver operator characteristic curves; TG/HDL-C, triglycerides to high-density lipoprotein-cholesterol ratio; TC/HDL-C, cholesterol to HDL-C ratio; FFA/HDL-C, free fatty acid to HDL-C ratio; UA/HDL-C, uric acid to HDL-C ratio; LDL-C/HDL-C, low-density lipoprotein-cholesterol to HDL-C ratio; APOB/A1, apolipoprotein B to apolipoprotein A1 ratio.
See this image and copyright information in PMC

References

    1. Ortiz-Lopez C, Lomonaco R, Orsak B, Finch J, Chang Z, Kochunov VG, et al. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care (2012) 35:873–8. doi: 10.2337/dc11-1849 - DOI - PMC - PubMed
    1. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol (2019) 71:793–801. doi: 10.1016/j.jhep.2019.06.021 - DOI - PubMed
    1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (2016) 64:73–84. doi: 10.1002/hep.28431 - DOI - PubMed
    1. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol (2013) 10:330–44. doi: 10.1038/nrgastro.2013.41 - DOI - PubMed
    1. Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. (2008) 51:444–50. doi: 10.1007/s00125-007-0897-4 - DOI - PubMed

Publication types